Risk Evaluation and Mitigation Strategies (REMS): Balancing Brand Justification and the Proper Role of Antitrust Enforcers.
11:30 AM GMT
Risk Evaluation and Mitigation Strategies (REMS) are designed to ensure the safe distribution of drugs; however, according to the recent GPhA report, REMS may be costing the American health care system $5.4 billion in annual pharmaceutical spending. Do brand manufacturers have valid justifications for restricting distribution? How should the courts balance potential efficienices of such behavior against potential anticompetitive effects? What should be the role of antitrust enforcers in examining and litigating REMS practices?
This panel, a follow-on discussion on the previous Health Care and Pharmaceuticals Committee REMS program that debated whether brand pharmaceutical companies have a duty to deal with generics, will explore these and other important questions surrounding the use of REMS.
* Robert Davis, Counsel, Venable LLP
* Alex Brill, CEO, Matrix Global Advisors
* Richard A. Feinstein, Partner, Boies Schiller & Flexner LLP
* Christine Meyer, Vice President, National Economic Research Associates
* Jan Rybnicek, Advisor to FTC Commissioner Joshua Wright, Federal Trade Commission
FREE: Antitrust Section Members, Government, Nonprofit Employees and Students
$25.00: Other Non-members
Learn about Section membership or call 800-285-2221 to join the source code: RAT14IP125. Instructions for accessing the live program will be provided in a confirmation email. For this and all upcoming events visit: http://AmBar.org/ATEvents.
The ABA is not seeking CLE credit for this program.
Provided all releases are obtained, MP3 recordings of this program will be available to Section members on the Committee Program Audio page.